Today, the EU4Health Civil Society Alliance launched Health4Europe—a strategic blueprint for the next EU Health Programme. Its goal is to ensure that health remains a top political and financial priority in the upcoming Multiannual Financial Framework (MFF), and to further strengthen the European Health Union.

Just days after presenting in Denver, the PAREA team travelled to Helsinki to participate in the European Academy of Neurology (EAN) Congress, a major event that also marked PAREA’s three-year anniversary.

Australia’s largest private health insurer, Medibank, has committed AUD $10 million (~EUR 6 million) to support patient access to MDMA-assisted therapy for PTSD, along with a health economics and outcomes study led by the Australian National University.

Earlier in June, PAREA’s Founder Tadeusz Hawrot participated in the REAL Summit London, a dynamic gathering of changemakers, investors, and innovators committed to transforming global mental health. Hosted by the REAL Mental Health Foundation, the event spotlighted urgent challenges in mental health care—most notably, the persistent stigma that continues to prevent millions from seeking help.

PAREA will be present next week at  Psychedelic Science 2025, in Denver, Colorado! 

PAREA has submitted a response to the European Commission’s open call for evidence on the EU Biotech Act: “Shaping the EU Biotech Act to Unlock Mental-Health Innovation”. We welcome this ambition, which has highlighted mental health as a critical priority.

The EU Drugs Agency (EUDA) has released its annual European Drug Report, focusing on emerging trends in the European drug market. It includes a chapter on the growing interest in psychedelics for therapeutic use.

The Czech Parliament has passed a significant law allowing psilocybin therapy for mental health conditions like depression, anxiety, and addiction.

The World Health Organization (WHO) has issued a rapid communication on its forthcoming guideline on controlled medicines, designed to support national policies that strike a balance between access and safety. PAREA was honoured to be invited to join the External Review Group for this new guideline.

A new European research network focused on psychedelics has been approved for funding under the COST (European Cooperation in Science and Technology) programme.

New PAREA Policy Paper: “Leading, not Lagging: Putting Mental Health at the Core of Europe’s Innovation and Competitiveness Agenda.”

On May 12, the Champalimaud Foundation hosted the official launch of Portugal’s Multidisciplinary Recommendations on the Clinical Use of Psychedelic Substances.

From April 28 to May 4, a landmark educational event on psychedelic therapy took place in Lviv, Ukraine, organised by the Multidisciplinary Association for Psychedelic Studies (MAPS) in partnership with the Ukrainian Psychedelic Research Association (UPRA). PAREA Founder & Executive Tadeusz Hawrot joined as an invited observer.

In April, PAREA Project Officer Francisca Silva took part in Breaking Convention - one of Europe’s largest and most diverse conferences on psychedelic research.

As part of the EU-funded PsyPal project, our Founder and Executive Director, Tadeusz Hawrot, recently participated in a two-day Design Thinking Workshop hosted by IESE Business School in Barcelona.

We’d like to extend a warm welcome to Reconnect Foundation, our newest Community Supporter!

PAREA has provided feedback on the European Commission’s initiative for a new multidisciplinary life sciences strategy, emphasising a clear message: mental health innovation should be a strategic priority on the agenda.

In a joint open letter from the EU4Health Civil Society Alliance (CSA) to Commission President Ursula von der Leyen, 35 organisations — including PAREA — urge the European Commission to take immediate action to secure stable and timely funding for health civil society organisations (CSOs).

PAREA’s annual Impact Report, compiling all our activities, contributions and achievements for the year of 2024, is now available!

The European Medicines Agency (EMA) has published the third revision of its “Guideline on the clinical investigation of medicinal products for the treatment of depression”, set to take effect in September 2025.